Collegium Pharmaceutical, Inc: Form 10-Q for the period ended Jun 30, 2016
Filed with the SEC on Aug 11, 2016 and accepted by EDGAR at Aug 11, 2016, 16:42 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2016-04-01 to 2016-06-30 | $4.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2016-01-01 to 2016-06-30 | $8.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-04-01 to 2016-06-30 | −$24.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2016-01-01 to 2016-06-30 | −$40.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2016-04-01 to 2016-06-30 | $46.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2016-01-01 to 2016-06-30 | $111.0k | us-gaap:InterestExpense |
| Net income | 3 months2016-04-01 to 2016-06-30 | −$24.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2016-01-01 to 2016-06-30 | −$40.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-04-01 to 2016-06-30 | −$1.05 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2016-01-01 to 2016-06-30 | −$1.73 | us-gaap:EarningsPerShareBasicAndDiluted |
| Basic EPS | 3 months2016-04-01 to 2016-06-30 | −$1.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2016-01-01 to 2016-06-30 | −$1.73 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2016-01-01 to 2016-06-30 | −$32.4m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months2016-01-01 to 2016-06-30 | $25.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2016-06-30 | $110.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-06-30 | $116.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-06-30 | $119.7m | us-gaap:Assets |
| Current liabilities | At period end2016-06-30 | $18.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-06-30 | $21.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-06-30 | $98.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-16-007925. Last ingested by Listed: Nov 10, 2026, 23:07 ET. Listed shows no prices and gives no investment advice.